Oxurion N.V.
0G99.L
London Stock Exchange0.27
EUR
+0.27
- -
Oxurion N.V.
0G99.L
(London Stock Exchange)
Recent
price
0.27
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, Belgium and founded in 1991, develops next-generation therapies to preserve vision in patients with retinal disorders including geographic atrophy and age-related macular degeneration; it specializes in acquiring majority stakes in promising European pharmaceutical subcontractors to build an integrated group serving healthcare stakeholders. The company offers ophthalmic treatments targeting unmet needs in ophthalmology, with a focus on cytoprotective targets identified through its CRISPR-based discovery platform; it holds a 72% stake in Axiodis CRO, a subcontractor specialized in biometrics for clinical research. Oxurion operates primarily in Europe, with research and development facilities in Belgium and strategic ambitions to expand across the continent as a hub for clinical data services. In 2025, Oxurion secured financing from Atlas Special Opportunities for its acquisition of Axiodis CRO, closing the transaction on August 1; it also obtained an improved indicative EUR 30 million financing offer in August to support diversification into clinical research technologies and published first-half 2025 financial results in September; additionally, the company signed a letter of intent in October for acquiring 80% of another CRO, valued at EUR 1.0375 million on a fully diluted basis, with exclusivity through December 31, 2025, to enhance end-to-end services from trial design to market access.